Biomedical Letters
2016 | Volume 2 | Issue 2|Pages 66-71

REVIEW ARTICLE OPEN ACCESS

Recent Approach in Medical Management of Fistulizing Crohn's Disease

Pawan Kumar, Zhanju Liu*

Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, China

Abstract
Crohn's disease is increasing in prevalence worldwide despite the biological treatment being associated with improved health related aspect of the human body. Fistulizing Crohn's disease is an emerging but still unclear issue for many authorities that accelerate from a complicated paradox among the genetic predisposition and environmental ramification. In fistulizing Crohn's disease, perianal fistula is very common, which correlate to grief with fatality in life. Thus a brief assessment with proper analysis of database and clinical practice guidelines are to be followed. In addition, with different modern and advanced modalities are required to determine the most suitable groundwork. Exploration undergoes beside the novel medicines and newer approaches, anti-TNF monoclonal antibodies (biologics) and gut selective agents including the dietary and lifestyle modification.
Keywords: Crohn's disease, Perianal fistula, inflammatory bowel disease, anti-TNF therapy.

Received July 21, 2016; **Revised** August 29, 2016; **Accepted** September 10, 2016
***Correspondence:** Zhanju Liu; **Email:** zhanjuliu@yahoo.com, **Contact**: +86 18917683431; Fax: +86-021-66303983

***To cite this manuscript*:** Kumar P, Liu Z. Recent Approach in Medical Management of Fistulizing Crohn's Disease. Biomed Lett 2016; 2(2):66-71.

Introduction

Crohn's disease is a chronic idiopathic transmural inflammatory process involving the gastrointestinal tract [1]. Localized gastritis of small intestine was first observed by Bissell in 1934 with perianal granulomatous contusion [2]. Anal fistula is the commonest perianal lesion whose incidence rate is 17%-43% [3-5]. At least one fistula occurs in their life in the 1/3rd patient with Crohn's Disease (CD). While most cases have two or more which are external with 55% peri-anal and 6% occupying the cutaneous tract. Remaining 1/3rd are internal tracts [6]. Usually perianal fistulas involve the perianal skin and others are observed in the genital (vulva and scrotum) region[7]. All the raised evidence displays the perianal fistula as a common drawback in CD. The major drawback of Perianal fistulas is perianal pain, swelling and abscess with sometimes discharge from the tract. In addition fever is mostly associated with abscess which further progress towards septicemia. So a relevant and convenient process is needed for its proper medication and healing. Thus a goal of medical therapeutics to cure the secretory activity and improve kind & nature of liveliness, prohibit septicemia & healing of tract [8].Further introduction of new biological therapy is helping to optimize the available medication better. Yet many elements are under development that could become drugs with additional proficient innovations & methodological meliorations for clinical trials. The paper intent towards contributing concise synopsis on recent scenario of different therapeutic drugs for the treatment of fistulizing crohn's disease used in clinical trials and also point out the adverse challenges associated with them for the safety of the patient.

Etiology

The etiology of anal fistulas in CD is still confusing. However to find out the advantages of therapeutic drugs, one must perceive the idea of pathogenesis of fistula formation. The hidden glandular approach takes part in anal ulceration in CD which not completely support the ideology [9]. Genetical and environmental components plays a role in the antimicrobial barrier of the gut against millions of bacteria and pathogens which causes injury and infections [10]. Inflammatory cellular loss points to transmural tissue underlying defect in the intestinal floor that is cytologically observed as cellular destruction penetrating into the deep layers of the gut wall [11]. The laminal fibrous cells supports healing fistula has less migratory actions with in the fistula patient. So the accurate tissue repair cannot occurs.[12]. The above cellular damage are seen by epithelialization as an alternative healing mechanism of the gut barrier[13]. Further, bacterial migration & expansion are engage in formation of fistulas rather skin derived bacteria are more involved microorganisms than the gut derived microbial vegetation [14]. Thus the entire processes of modulation of inflammatory processes for fistula

formation are well studied and antibacterial strategies are applied to minimize the bacterial load.

Classification

Perianal CD is classified according to the anatomical tract and in terms of the disease breakthrough. The classification given by Park for anal fistulas describes the primary and secondary extensions [15] which is applied to the CD. Distribution about fistula progress consists the Fistula Drainage Assessment and Perianal disease Activity Index. Magnetic resonance imaging (MRI) based scoring system also exist to evaluate the response to remedy [16], although the action of classifications is of limited value in the clinical settings [17].

Diagnosis and investigation

Different modalities are used as a diagnostic tool for the analysis of CD. Although a physical examination is needed to assess the presence of perianal lesions such as (stenosis, fissure, ulcer etc), the number of orifices and flowing pus. Active luminal disease is diagnosed by the Endoscope. Colonoscopy along ileoscopy including biopsy is necessary in the diagnosis of CD at the junction of the ileum and colon [18]. While doing endoscopy one may finds the skin lesions, cobblestoning, ulcerations and strictures. Capsule endoscopy is another important tool for the assessment of small bowel CD including Computed Tomography scan, magnetic resonance imaging and small gut follow through examinations. Skip Capsule Endoscopy in patients with small bowel strictures because capsule retention may occurs. Esophagogastroduodenoscopy is recommended in patients with upper GI symptoms; asymptomatic patients with iron deficiency anemia; and patients with active CD who have normal colonoscopy findings [18]. Other diagnostic tools include Magnetic resonance imaging (MRI), Endoanal Ultrasonography (EUS) and Trans-perianal ultrasonography (TPUS). MRI is more relevant in comparison to EUS & TPUS to overview the primary and secondary elongations [19], although do not confess the internal orifices. EUS is more appropriate in determining the internal openings with its relevant tracts. MRI and EUS are 100% accurate [20]. MRI also guides in medical treatment as clinical evaluation sometimes misses the occult and unhealed tracts of the patients in remission. Thus in such patients, deep healing has shown to occur a median of 12 months after the closure of the external orifices [17, 21]. MRI evaluation with 3D models displays promising in monitoring response to the treatment of the fistulizing crohn's disease [22]. Along with those, it convey to exploration of serological markers being atypical perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA)[23]. pANCA are antibodies formed against proteins in the nuclear lamina of the neutrophils, while ASCA are antibodies against mannose epitopes from the yeast Saccharomyces cerevisiae [24]. The ultimate test for crohn's disease was sera with positive ASCA and weak pANCA, 52%-64% and 92%- 94%, respectively[25].

Risk Elements

The peak age prevalence of Crohn's disease is 30-39 years with the gender influence various populations. 10%-13% women are affected than the males in a Canadian and New Zealand people [26] [27]. But the male's ratio are three times higher in CD in Japan and Korea [28, 29]. The cause is anonymous. It seems to be complicated reciprocal action among genetic propensity, environmental exposure and immune deterioration to the colonal endothelium [30]. genetic influence is seen in co- twin German review[31]. Many young generations has more familial augmentation [32]. A jewish demography display immense preponderance Jewish rates although varying prevalence in different geographic territory suggests the influence of environmental circumstances[33]. Smoking should be prohibited. OCP in females are to be minimized. Balanced dietary are to be inspired along higher fiber contents and fruits have shown to be protective against the crohn's disease [34].

Medical Treatment

The decisions in the management of fistulizing crohn's disease should always be made through discussion between the multidisciplinary team. Aim of the analysis is to minimized manifestation, control and maintenance of remission with minimal injurious reaction [35].

Mesalazine (5-aminosalicylic acid) did not show any effect on fistulizing crohn's disease[36]. Steroids act as active anti-inflammatory effect which are effective in the active management of CD but have no positive effects on fistula healing. Many drawback are noted, although had been used as medication [7, 37]. The statistical clinical trials show the efficacy of many medications, the fistula heals in 6%-13% [38, 39].

1. Antibiotics

Antibiotics Ciprofloxacin[40] and Metronidazole) are the first line therapy for the treatment of fistulizing CD which has been claimed to reduce discharge and improve manifestation. Metronidazole is a leading antibiotic preparation for perianal CD even though the evidence is only based on three researches [41-43]. Prognosis with Metronidazole can be seen within 6-8 weeks [41] and the closure of the fistula rate 50% [43]. But the recurrence rate is 80% after the cessation of metronidazole [42]. Longstanding utility of metronidazole has many side effects like metallic taste, tongue inflammation, vomiting, digestive discomfort and neuropathy [44]. Thus metronidazole has excellent efficacy rate for fistula healing. Ciprofloxacin with metronidazole showed the clinical response within 12 weeks of administration in about 60% of patients with severe complex fistulas and 20% even show fistula termination. An analyzing research within ciprofloxacin to metronidazole on a small group (25 patients) showed after 10 weeks of treatment, ciprofloxacin finds much preferable to metronidazole in 30% patient treated with ciprofloxacin had fistula closure whereas 0% result with metronidazole. Cessation of therapy before 10^{th} week occurred in 71.4% in the metronidazole group and 10% in the ciprofloxacin classes [45].Drawback to ciprofloxacin are uncommon but shows headache, vomiting, loose stool and sometime rash[46].But more analysis are required due to the small sample size.

2. Calcineurin Inhibitors

Calcineurin Inhibitors has a significant role in a fistulizing CD [47].They has good short duration efficacy rate, yet fistula again reappear after its stoppage. A randomized study in 2003 done by Sandborn [48]. Narrow fistula wall was observed in 43% patients compared to 8% in the trial group. However, fistula rate among the two groups were 8%in placebo and 10% to Tacrolimus. Deliberate negative impact are observed with raised serum creatinine level which further proceeds to nephrotoxicity that can be prevent by the minimizing dose. Further trial of ten patients by Gonzalez-Lama [49]. Cyclosporine when used IV in 88% of patients shows a good response while 44% shows fistula closure[50], that were approved by further analysis[51, 52]. The adverse drawback by cyclosporine shows seizure, raised blood pressure, renal injury and septicemia [53].

2.1 Thiopurines

It is an immunosuppressive drug which belongs to purine group. It suppress the nucleic acid production and performs the anti- proliferative effect on active lymphocytes and induces cell lysis [54]. They show excellent effects on induction & continue remission in luminal CD [55]. A 5 meta- analysis of randomized trials in which fistula closure was a secondary endpoint shows the beneficial effects of azathioprine and 6-mercaptopurine in 54% patients, while 21% only react to the placebo group [56] but a more recent Cochrane review failed to demonstrate any favor[57] .More fistula healing with 6-mercaptopurine was observed by Present [58].Thus, azathioprine/6-mercaptopurine may be used as a primary treatment but is rarely sufficient alone.

3. Anti-TNF –Alpha Therapy

After the introduction of anti –TNF –alpha agents, it has gained the milestone to the medical treatment of fistulizing CD. Infliximab is a monoclonal part of TNF-α which has quick disease reduction properties and improve the patient's quality of life. First anti-TNF-alpha for a placebo controlled trial infliximab. A randomized study on 94 patients, at least one secreting fistula compared infliximab at the dose of 5 or 10mg/kg with placebo [59]. 5mg/kg infliximab was given intravenously for induction on weeks 0, 2, 6. Another maintenance dose was given on week 8. ACCENT II study verifies the potency to infliximab as a maintenance therapy in fistulizing CD. 90% patient shows perianal fistula & around half had only one fistula opening [59]. 62% patient reformed and 56% obtained fistula closure out of the treated patient within a median of 2 weeks of the onset of their feedback.12 months of maintenance dose had proven better than placebo in countering relapse, although half of infliximab having patient observe a recurrence with in the 1st year of therapy [3, 60].

Adalimumab was tested in CHARM trial in 2007. 30% had fistula closure after 26 weeks compared to placebo 13% cessation rate. The ultimate response was observed after week 56 [61].39% patients had a complete fistula healing and good quality of life who had previously failed to infliximab treatment [62].

3.1 Certolizumab

Certolizumab pegol is a human anti-TNF monoclonal antibody approved for the treatment in CD since 2007. Two studies PRECISE I & II are done [63, 64]. No compelling divergence seen between placebo and certolizumab treatment groups regarding the cessation of fistula. At 26 weeks, healing of fistula

were seen in 36% of the treatment groups & 17% in placebo groups respectively [63]. The study also indicate that early intervention with certolizumab improves both response and remission rates. The negative drawbacks were nasal discharge, common cold, loose stool, UTI, and sometimes septicemia with heart failure [65].

3.2 Natalizumab

Natalizumab is another humanized monoclonal antibody was approved in 2008 which works by binding the selective adhesin molecule with (α) 4-integrin, & suppress leukocyte chemotaxis within intestine [66]. Data express natalizumab are more active in moderate to severe fistulizing CD, especially to those which are ineffective to alternative treatment, along with anti-TNF drugs [67]. The leading negative feedback was revivation of human JC virus leading to Progressive multifocal Leukoencephalopathy (PML), observed in two patients suffering from multiple sclerosis and another with isolated CD, inducing fresh analysis. A study showed 3500 patients having natalizumab, no recent PML cases are seen [68]. For that a TOURCH program were started before switching to natalizumab. It is avoided in old age, immune compromised & patient using immunomodulators regularly.

4. Anti-Integrin Antibody (Vedolizumab)

Vedolizumab is a recently launched novel agent monoclonal anti- integrin antibody marking α4β7. It acts by forbidding action of α4β7 integrin with MAdCAM-1 on the endothelial cells and hence it prohibits the migration of T-lymphocytes into the mucosal cells. GEMINI II & III trials shows, vedolizumab had good clinical response and remission on active CD [69]. Although, more trial are needed to investigate the future analysis of vedolizumab. Even the transfer of T-lymphocytes into the gut wall is a better encouraging approach for the treatment of fistulizing crohn's disease.

5. New Local treatment for fistula (Fibrin Glue/Plugs/Laser)

It is a platelet rich fibrin plaque which is used by sealing the fistula tract. Though prevalence rate are high and has a less negative impact, it is safe & easy superior to the other therapy, gives patient comfort, not altered sphincter function, minimal hospital stay, less pain and complications with other adverse reactions. Recent prospective study shows [70], 66.66% fistulas closure rate with zero rate of fecal incontinence. Fibrin plugs were organic substance achieved from porcine gut mucosa. Though small uncontrolled trial with relatively short observation times and incompatible plug materials had been published[71]. Carbon dioxide laser ablation is alternative therapy in perianal CD [72].

5.1 Local infliximab installation and stem cells

The application in the fistula tract of autologous stem cells is derived from adipose tissue. Modern therapies are still being researched. But recent available evidence are very limited for these methods to be recommended.

Conclusion

There are still certain challenges in the evidence regarding diagnosis & management of patients with fistulizing Crohn's disease. Every Patients should be examined individually to determine which investigation is much convenient, observing the disease location, its severity and chances of recurrence. Many modern imaging facilities and serological studies have assisted for both diagnosis & monitoring of fistula in CD. The goal of treatment is to recover without concealing the maintenance therapy. Antibiotic is started initially. Prompt decrement in discharge is seen but may need a bridging approach to immunosuppressive therapy that proves to be more efficient in fistulizing CD. Few with complex fistula abscess need surgical repair and some ultimately need proctectomy.

Although with widening medical growth, randomized control studies about fistula healing is still insufficient. Hence management costom mostly depend upon retrospective reviews from large specialty medical centers. So more fresh research & analysis are needed for estimating the efficacy of certain novel therapeutic agents and their role in active fistulizing CD compared with classic anti-TNF therapy.

Conflict of interest

The authors declare no conflicts of interest.

References

[1] Deepak P, Bruining DH. Update on the Medical Management of Crohn's Disease. Current gastroenterology reports. 2015;17:41.

[2] Yang BL, Chen YG, Gu YF, Chen HJ, Sun GD, Zhu P, et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World journal of gastroenterology. 2015;21:2475-82.

[3] Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. The New England journal of medicine. 2004;350:876-85.
[4] Ardizzone S, Porro GB. Perianal Crohn's disease: overview. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2007;39:957-8.
[5] Chung W, Kazemi P, Ko D, Sun C, Brown CJ, Raval M, et al. Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. American journal of surgery. 2009;197:604-8.
[6] Klag T, Goetz M, Stange EF, Wehkamp J. Medical Therapy of Perianal Crohn's Disease. Viszeralmedizin. 2015;31:265-72.
[7] Vavricka SR, Rogler G. Fistula treatment: The unresolved challenge. Digestive diseases (Basel, Switzerland). 2010;28:556-64.
[8] Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, et al. Management of perianal fistulas in Crohn's disease: an up-to-date review. World journal of gastroenterology. 2015;21:1394-403.
[9] Parks AG. Pathogenesis and treatment of fistuila-in-ano. British medical journal. 1961;1:463-9.
[10] Klag T, Stange EF, Wehkamp J. Defective antibacterial barrier in inflammatory bowel disease. Digestive diseases (Basel, Switzerland). 2013;31:310-6.
[11] Bataille F, Klebl F, Rummele P, Schroeder J, Farkas S, Wild PJ, et al. Morphological characterisation of Crohn's disease fistulae. Gut. 2004;53:1314-21.
[12] Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Goke M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125:1341-54.
[13] Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Digestive diseases and sciences. 2005;50 Suppl 1:S24-33.
[14] West RL, Van der Woude CJ, Endtz HP, Hansen BE, Ouwedijk M, Boelens HA, et al. Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment? Digestive diseases and sciences. 2005;50:1260-3.
[15] Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. The British journal of surgery. 1976;63:1-12.
[16] Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. The American journal of gastroenterology. 2003;98:332-9.
[17] Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. The American journal of gastroenterology. 2009;104:2973-86.
[18] Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:i1-15.
[19] Sahni VA, Ahmad R, Burling D. Which method is best for imaging of perianal fistula? Abdominal imaging. 2008;33:26-30.
[20] Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology. 2001;121:1064-72.
[21] Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflammatory bowel diseases. 2012;18:1825-34.
[22] Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Alimentary pharmacology & therapeutics. 2014;40:741-9.
[23] Bossuyt X. Serologic markers in inflammatory bowel disease. Clinical chemistry. 2006;52:171-81.
[24] van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62:683-8.
[25] Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflammatory bowel diseases. 2012;18:1340-55.
[26] Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. The American journal of gastroenterology. 2006;101:1559-68.
[27] Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflammatory bowel diseases. 2006;12:936-43.
[28] Kim HJ, Hann HJ, Hong SN, Kim KH, Ahn IM, Song JY, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflammatory bowel diseases. 2015;21:623-30.
[29] Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Diseases of the colon and rectum. 2000;43:S85-93.
[30] Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Current gastroenterology reports. 2007;9:497-507.
[31] Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflammatory bowel diseases. 2008;14:968-76.
[32] Bengtson MB, Solberg C, Aamodt G, Jahnsen J, Moum B, Sauar J, et al. Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. Inflammatory bowel diseases. 2009;15:1867-74.
[33] Fireman Z, Grossman A, Lilos P, Eshchar Y, Theodor E, Gilat T. Epidemiology of Crohn's disease in the Jewish population of central Israel, 1970-1980. The American journal of gastroenterology. 1989;84:255-8.
[34] Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. The American journal of gastroenterology. 2011;106:563-73.
[35] Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. The American journal of gastroenterology. 2005;100:2225-9.
[36] Nielsen OH, Rogler G, Hahnloser D, Thomsen OO. Diagnosis and management of fistulizing Crohn's disease. Nature clinical practice Gastroenterology & hepatology. 2009;6:92-106.
[37] Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-66.
[38] Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn's disease. Alimentary pharmacology & therapeutics. 2006;24:1283-93.
[39] Pascua M, Su C, Lewis JD, Brensinger C, Lichtenstein GR. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Alimentary pharmacology & therapeutics. 2008;28:545-56.
[40] Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115:1072-8.
[41] Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79:599.
[42] Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982;83:383-7.

[43] Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. The American journal of gastroenterology. 1984;79:533-40.
[44] Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679-708.
[45] Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflammatory bowel diseases. 2009;15:17-24.
[46] Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019-74.
[47] McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn's disease. The Cochrane database of systematic reviews. 2005:Cd000297.
[48] Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380-8.
[49] Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflammatory bowel diseases. 2005;11:8-15.
[50] Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Digestive diseases and sciences. 1994;39:374-80.
[51] Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. The American journal of gastroenterology. 1998;93:442-8.
[52] Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. The American journal of gastroenterology. 1993;88:646-9.
[53] Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflammatory bowel diseases. 2014;20:2151-6.
[54] Schroll S, Sarlette A, Ahrens K, Manns MP, Goke M. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regulatory peptides. 2005;131:1-11.
[55] Bar F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World journal of gastroenterology. 2013;19:1699-706.
[56] Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Annals of internal medicine. 1995;123:132-42.
[57] Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. The Cochrane database of systematic reviews. 2010:Cd000545.
[58] Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. The New England journal of medicine. 1980;302:981-7.
[59] Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. The New England journal of medicine. 1999;340:1398-405.
[60] Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews. 2008:Cd006893.
[61] Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
[62] Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Alimentary pharmacology & therapeutics. 2010;32:1228-39.
[63] Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Alimentary pharmacology & therapeutics. 2011;33:185-93.
[64] Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. The New England journal of medicine. 2007;357:239-50.
[65] Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. The New England journal of medicine. 2007;357:228-38.
[66] Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. The New England journal of medicine. 2003;348:24-32.
[67] Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-83.
[68] MacDonald J, McDonald JW. Natalizumab for induction of remission in Crohn's disease. The Cochrane database of systematic reviews. 2007:Cd006097.
[69] Poole RM. Vedolizumab: first global approval. Drugs. 2014;74:1293-303.
[70] Lara FJ, Serrano AM, Moreno JU, Carmona JH, Marquez MF, Perez LR, et al. Platelet-rich fibrin sealant as a treatment for complex perianal fistulas: a multicentre study. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015;19:360-8.
[71] Mishra A, Shah S, Nar AS, Bawa A. The role of fibrin glue in the treatment of high and low fistulas in ano. Journal of clinical and diagnostic research : JCDR. 2013;7:876-9.
[72] Moy J, Bodzin J. Carbon dioxide laser ablation of perianal fistulas in patients with Crohn's disease: experience with 27 patients. American Journal of Surgery. 2006;191:424-7.